Zoekresultaten - Jayakumar R. Nair

  • Toon 1 - 16 resultaten van 16
Verfijn jouw resultaten
  1. 1
    Sec2 protein contains a coiled-coil domain essential for vesicular transport and a dispensable carboxy terminal domain.

    Sec2 protein contains a coiled-coil domain essential for vesicular transport and a dispensable carboxy terminal domain. door Jayakumar R. Nair, Heike Müller, Michelle Peterson, Peter Novick

    Gepubliceerd in 1990
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type high-grade serous ovarian cancer

    Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases <i>in vitro</i> toxicity of PARP inhibition by preventing Rad51 foci formation in <i>BRCA</i> wild type hi... door Ethan Brill, Takuhei Yokoyama, Jayakumar R. Nair, Minshu Yu, Lucie Ahn, Jung‐Min Lee

    Gepubliceerd in 2017
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  3. 3
    Novel Regulation of CD80/CD86-induced Phosphatidylinositol 3-Kinase Signaling by NOTCH1 Protein in Interleukin-6 and Indoleamine 2,3-Dioxygenase Production by Dendritic Cells

    Novel Regulation of CD80/CD86-induced Phosphatidylinositol 3-Kinase Signaling by NOTCH1 Protein in Interleukin-6 and Indoleamine 2,3-Dioxygenase Production by Dendritic Cells door Chandana Koorella, Jayakumar R. Nair, Megan Murray, Louise Carlson, Stephanie K. Watkins, Kelvin P. Lee

    Gepubliceerd in 2014
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  4. 4
    Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

    Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer door Jayakumar R. Nair, Tzu‐Ting Huang, Junko Murai, Brittany Haynes, Patricia S. Steeg, Yves Pommier, Jean C. Lee

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  5. 5
    Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma

    Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma door Jayakumar R. Nair, Justin Caserta, Krista Belko, Tyger L Howell, Gerald J. Fetterly, Carmen M. Baldino, K P Lee

    Gepubliceerd in 2016
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  6. 6
    Sustained antibody responses depend on CD28 function in bone marrow–resident plasma cells

    Sustained antibody responses depend on CD28 function in bone marrow–resident plasma cells door Henryk Różański, Ramon Arens, Louise Carlson, Jayakumar R. Nair, Lawrence Boise, Asher Chanan‐Khan, Stephen P. Schoenberger, Kelvin P. Lee

    Gepubliceerd in 2011
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  7. 7
    CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma

    CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma door Megan Murray, Catherine M. Gavile, Jayakumar R. Nair, Chandana Koorella, Louise Carlson, Daniela Buac, Adam Utley, Marta Chesi, P. Leif Bergsagel, Lawrence Boise, Kelvin P. Lee

    Gepubliceerd in 2014
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  8. 8
    CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment

    CD28 Expressed on Malignant Plasma Cells Induces a Prosurvival and Immunosuppressive Microenvironment door Jayakumar R. Nair, Louise Carlson, Chandana Koorella, Henryk Różański, Gerald E. Byrne, P. Leif Bergsagel, John P. Shaughnessy, Lawrence Boise, Asher Chanan‐Khan, Kelvin P. Lee

    Gepubliceerd in 2011
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  9. 9
    KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells

    KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells door Sudha Mannava, Dazhong Zhuang, Jayakumar R. Nair, Rajat Bansal, Joseph A. Wawrzyniak, Shoshanna N. Zucker, Emily E. Fink, Kalyana Moparthy, Qiang Hu, Song Liu, Lawrence Boise, Kelvin P. Lee, Mikhail A. Nikiforov

    Gepubliceerd in 2011
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  10. 10
    A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast Cancer

    A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in <i>BRCA</i> Wild-Type, Advanced Triple-Negative Breast Cancer door Margaret E. Gatti‐Mays, Fatima Karzai, Sanaz Soltani, Alexandra S. Zimmer, Jeffrey E. Green, Min-Jung Lee, Jane B. Trepel, Akira Yuno, Stanley Lipkowitz, Jayakumar R. Nair, Ann McCoy, Jung Min Lee

    Gepubliceerd in 2020
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  11. 11
    Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells

    Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells door Emily E. Fink, Sudha Mannava, Archis Bagati, Anna Bianchi, Jayakumar R. Nair, Kalyana Moparthy, Brittany C. Lipchick, Mikhail Drokov, Andrea Utley, Jason Ross, Л. П. Менделеева, Savchenko Vg, K P Lee, Mikhail A. Nikiforov

    Gepubliceerd in 2015
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  12. 12
    CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif

    CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif door Henryk Różański, Adam Utley, Louise Carlson, Matthew R. Farren, Megan Murray, Lisa Russell, Jayakumar R. Nair, Zhengyu Yang, William Brady, Lee Ann Garrett‐Sinha, Stephen P. Schoenberger, Jonathan M. Green, Lawrence Boise, Kelvin P. Lee

    Gepubliceerd in 2015
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  13. 13
    Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study

    Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study door Jung‐Min Lee, Jayakumar R. Nair, Alexandra S. Zimmer, Stanley Lipkowitz, Christina M. Annunziata, Maria J. Merino, Elizabeth M. Swisher, Maria I. Harrell, Jane B. Trepel, Min-Jung Lee, Mohammadhadi Bagheri, Dana‐Adriana Botesteanu, Seth M. Steinberg, Lori M. Minasian, Irene Ekwede, Elise C. Kohn

    Gepubliceerd in 2018
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  14. 14
    <i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer

    <i>BLM</i> overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant <i>BRCA</i> -mutant ovarian cancer door Nitasha Gupta, Tzu‐Ting Huang, Jayakumar R. Nair, Daniel An, Grant Zurcher, Erika J. Lampert, Ann McCoy, Ashley Cimino‐Mathews, Elizabeth M. Swisher, Marc R. Radke, Christina M. Lockwood, Jonathan Reichel, Chih-Yuan Chiang, Kelli M. Wilson, Ken Cheng, Darryl Nousome, Jung‐Min Lee

    Gepubliceerd in 2023
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  15. 15
    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

    The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial door Elena Giudice, Tzu‐Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen R. Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, N Sato, Jane B. Trepel, Jung‐Min Lee

    Gepubliceerd in 2024
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  16. 16
    Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

    Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study door Erika J. Lampert, Alexandra S. Zimmer, Michelle R. Padget, Ashley Cimino‐Mathews, Jayakumar R. Nair, Yingmiao Liu, Elizabeth M. Swisher, James W. Hodge, Andrew B. Nixon, E. Hitt Nichols, Mohammadhadi Bagheri, Elliott Levy, Marc R. Radke, Stanley Lipkowitz, Christina M. Annunziata, Janis M. Taube, Seth M. Steinberg, Jung‐Min Lee

    Gepubliceerd in 2020
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: